Acupuncture and cognition: a short-term signal, with no evidence of lasting benefit

Nine trials, different interventions

The authors pooled nine randomized trials published between 2015 and 2025, involving 614 participants. After dropouts, 599 people completed the studies. The review combines trials of manual acupuncture and electroacupuncture, so its findings cannot attribute the entire signal to the latter.

The PubMed abstract, the only part consulted for this dossier, does not detail the comparator groups or the duration of each trial. This information is needed to assess precisely what the intervention adds compared with usual care or a sham intervention.

Improved scores, not a slowing of the disease

The pooled analyses report short-term improvements in MoCA and MMSE scores, two cognitive assessment tests, as well as a decrease in IL-6, a peripheral inflammatory marker. The pooled effects were slightly larger in participants with mild cognitive impairment than in those with early-stage Alzheimer’s disease.

However, the abstract provides neither numerical effect sizes nor uncertainty intervals. This dossier therefore cannot establish whether the gains are large enough to translate into a noticeable difference in everyday life. A decrease in IL-6 also does not, on its own, demonstrate reduced inflammation in the brain.

These results prove neither dementia prevention nor a lasting slowing of the disease. Nor do they support a conclusion of benefit in someone without cognitive impairment.

NLRP3: a biological hypothesis, not clinical proof

The review also explores the NLRP3 inflammasome, a cellular system involved in inflammatory responses. In the preclinical models of aging described, its excessive activation contributes to processes associated with neuronal damage and cognitive decline.

The authors propose that acupuncture could act on several pathways linked to this system, including cellular recycling, oxidative stress and certain responses of the brain’s immune cells. This protective network remains a hypothesis based on preclinical data. The cognitive results from human trials do not demonstrate that this mechanism explains the improvements observed.

Standardization remains a major problem

Acupuncture points, electrical stimulation parameters and treatment cycles vary widely across trials. This heterogeneity limits comparisons between them and the reproducibility of their results.

The authors propose a provisional framework for standardizing mechanistic research, not a protocol for routine practice. The abstract does not allow an assessment of adverse effects, excluded populations, funding or conflicts of interest. A signal of efficacy is therefore not enough here to establish the benefit–risk balance.

What we can take away

This review supports better-standardized trials, not a promise of brain protection. It suggests a possible short-term cognitive gain in people already affected, without establishing its clinical significance or duration.